Journal article
Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis.
Abstract
OBJECTIVE: Dulaglutide (DU) 1.5 mg was associated with improved composite renal outcomes that included new-onset macroalbuminuria in people with type 2 diabetes with previous cardiovascular disease or cardiovascular risk factors in the REWIND (Researching cardiovascular Events with a Weekly INcretin in Diabetes) trial. This exploratory post hoc analysis evaluated kidney function-related outcomes, excluding the new-onset macroalbuminuria …
Authors
Botros FT; Gerstein HC; Malik R; Nicolay C; Hoover A; Turfanda I; Colhoun HM; Shaw JE
Journal
Diabetes Care, Vol. 46, No. 8, pp. 1524–1530
Publisher
American Diabetes Association
Publication Date
August 1, 2023
DOI
10.2337/dc23-0231
ISSN
0149-5992